Minoryx is a clinical stage biotech company leading the development of new therapies for X-ALD and other rare diseases with a high unmet medical need. The company’s leading program is MIN-102, a novel, orally bioavailable and selective PPAR gamma agonist with a superior profile for central nervous system-related diseases. It is currently in an ongoing phase 2/3 clinical trial for the treatment of adrenomyeloneuropathy (AMN) in EU and US. The trial enrolls adult male patients affected by AMN, the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD), in Europe and the US, with results expected in 2020. Please visit http://www.minoryx.com/.
Minoryx is expanding its activities and potential indications for MIN-102 and is now launching a clinical trial in a second orphan CNS indication (Friedreich’s Ataxia). Recently the company opened a second R&D site at the i-Tech Incubator (Brussels South Biopark – Charleroi, Belgium). The company is backed by a syndicate of experienced investors and has support from a network of other organizations. Minoryx was founded in 2011 and has raised more than €50M, including a €21.3M Series B closed in September 2018.
Minoryx is actively looking for a candidate for the position of CMC MANAGER (m/f). The candidate will be located in the Belgian subsidiary but would be expected to maintain close contact with the team located at the HQ in Mataró (Barcelona, Spain) and will be reporting to the Director of CMC. The position includes travels to visit CDMOs as needed.
